NLRP3 and metabolic dysfunction-associated steatotic liver disease: Liu et al proposes that improving Foxo3a-Bim transcription-facilitating autophagy flux-inhibiting NLRP3 inflammasome activation axis can be a target for treating NAFLD.[47] The feature of NASH is reduced autophagy flux and activated inflammasomes.